Accepted for publication EANM 2010

Development of a Radiosynthesizer Module Designed to Produce Florbetapir F 18 \(^{18}\text{F-AV-45}\) for Clinical Trials

Authors: Leandro Silva\(^1\), Pablo Pace\(^1\), Carlos Hormigo\(^1\), Patricia Zubata\(^1\), Natalia Leonardi\(^1\), Marcela Zubillaga\(^1\), Jorge Nicolini\(^1\), Ricardo Caro\(^1\), Guillermo Casale\(^1\), Nathaniel C. Lim\(^2\), Tyler E. Benedum\(^2\)

\(^1\)Laboratorios BACON SAIC Buenos Aires Argentine  \(^2\) Avid Radiopharmaceuticals Inc., Philadelphia, Pennsylvania;

Abstract:

Florbetapir F 18 is a radiopharmaceutical used for imaging β amyloid deposits in clinical trials in Argentine. Laboratorios BACON has pursued producing this imaging agent locally in the cyclotron facility.

The IBA Synthera has been a reliable platform for producing 18F-FDG worldwide via nucleophilic exchange of the radionuclide 18F. This reliability, together with its versatility makes an ideal combination for adapting more complicated processes (compared to 18F-FDG production) into the Synthera platform. We report herein, an IBA Synthera platform adapted synthesis of florbetapir F 18 wherein an HPLC semi preparative purification system and a reformulation module has been successfully integrated. The resulting system is highly reliable and capable of producing highly pure product (both radio-chemically and chemically) with high specific activity.